DPP4 and metabolic dysfunction-associated steatohepatitis: Aside from their inhibitory effects on insulin resistance and macrophage activation in NASH, DPP4 inhibitors have been reported to suppress the progression of NASH-related HCC through downregulation of nucleotide production [87].